These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 16133384)
1. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Gabriel M; Hausler F; Bale R; Moncayo R; Decristoforo C; Kovacs P; Virgolini I Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1440-51. PubMed ID: 16133384 [TBL] [Abstract][Full Text] [Related]
2. Incremental value of Trogrlic M; Težak S Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207 [TBL] [Abstract][Full Text] [Related]
3. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. Gabriel M; Decristoforo C; Kendler D; Dobrozemsky G; Heute D; Uprimny C; Kovacs P; Von Guggenberg E; Bale R; Virgolini IJ J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086 [TBL] [Abstract][Full Text] [Related]
4. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT. Madrzak D; Mikołajczak R; Kamiński G Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886 [TBL] [Abstract][Full Text] [Related]
5. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Castaldi P; Rufini V; Treglia G; Bruno I; Perotti G; Stifano G; Barbaro B; Giordano A Radiol Med; 2008 Oct; 113(7):1056-67. PubMed ID: 18797822 [TBL] [Abstract][Full Text] [Related]
6. SPET/CT image co-registration in the abdomen with a simple and cost-effective tool. Förster GJ; Laumann C; Nickel O; Kann P; Rieker O; Bartenstein P Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):32-9. PubMed ID: 12483407 [TBL] [Abstract][Full Text] [Related]
7. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Pfannenberg AC; Eschmann SM; Horger M; Lamberts R; Vonthein R; Claussen CD; Bares R Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):835-43. PubMed ID: 12682789 [TBL] [Abstract][Full Text] [Related]
8. Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis. Ingui CJ; Shah NP; Oates ME Clin Nucl Med; 2006 Nov; 31(11):665-72. PubMed ID: 17053381 [TBL] [Abstract][Full Text] [Related]
9. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity? Steffen IG; Mehl S; Heuck F; Elgeti F; Furth C; Amthauer H; Ruf J Clin Nucl Med; 2009 Dec; 34(12):869-73. PubMed ID: 20139819 [TBL] [Abstract][Full Text] [Related]
10. Specificity and sensitivity of ⁹⁹mTc-EDDA/HYNIC-Tyr³-octreotide (⁹⁹mTc-TOC) for imaging neuroendocrine tumors. Sepúlveda-Méndez J; de Murphy CA; Pedraza-López M; Murphy-Stack E; Rojas-Bautista JC; González-Treviño O Nucl Med Commun; 2012 Jan; 33(1):69-79. PubMed ID: 21970835 [TBL] [Abstract][Full Text] [Related]
11. The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC. Artiko V; Sobic-Saranovic D; Pavlovic S; Petrovic M; Zuvela M; Antic A; Matic S; Odalovic S; Petrovic N; Milovanovic A; Obradovic V J BUON; 2012; 17(3):537-42. PubMed ID: 23033296 [TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma. Yamamoto Y; Nishiyama Y; Monden T; Matsumura Y; Satoh K; Ohkawa M J Nucl Med; 2003 Dec; 44(12):1905-10. PubMed ID: 14660715 [TBL] [Abstract][Full Text] [Related]
13. Mapping of treatment-induced apoptosis in normal structures: 99mTc-Hynic-rh-annexin V SPECT and CT image fusion. Kartachova MS; Valdés Olmos RA; Haas RL; Hoebers FJ; van den Brekel MW; van Zandwijk N; Herk Mv; Verheij M Eur J Nucl Med Mol Imaging; 2006 Aug; 33(8):893-9. PubMed ID: 16586080 [TBL] [Abstract][Full Text] [Related]
14. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671 [TBL] [Abstract][Full Text] [Related]
15. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors. Trogrlic M; Tezak S Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884 [TBL] [Abstract][Full Text] [Related]
16. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Gabriel M; Muehllechner P; Decristoforo C; von Guggenberg E; Kendler D; Prommegger R; Profanter C; Moncayo R; Virgolini I Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):237-44. PubMed ID: 16172569 [TBL] [Abstract][Full Text] [Related]
17. The usefulness of 99mTc-tetrofosmin SPECT in the detection of lung metastases from extrapulmonary primary tumors. Spanu A; Solinas ME; Farris A; Arru A; Chessa F; Madeddu G; Falchi A; Madeddu G Radiol Med; 2004; 107(1-2):113-27. PubMed ID: 15031703 [TBL] [Abstract][Full Text] [Related]
18. Technetium-99m-labelled red blood cell imaging in the diagnosis of hepatic haemangiomas: the role of SPECT/CT with a hybrid camera. Schillaci O; Danieli R; Manni C; Capoccetti F; Simonetti G Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1011-5. PubMed ID: 15057491 [TBL] [Abstract][Full Text] [Related]
19. Added value of SPECT/CT in patients suspected of having bone infection: preliminary results. Horger M; Eschmann SM; Pfannenberg C; Storek D; Vonthein R; Claussen CD; Bares R Arch Orthop Trauma Surg; 2007 Apr; 127(3):211-21. PubMed ID: 17146681 [TBL] [Abstract][Full Text] [Related]
20. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Wong KK; Cahill JM; Frey KA; Avram AM Acad Radiol; 2010 Mar; 17(3):291-7. PubMed ID: 19962915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]